Executive Summary
The IPO Pipeline stream on March 17, 2026, captures two high-materiality filings: Rallybio Corp's S-4 for its merger with Candid Therapeutics (mixed sentiment) and AmperCap Acquisition Company's S-1 for a $125M SPAC IPO (neutral sentiment). Both entities exhibit no revenues to date, reflecting pre-operational stages with zero YoY/QoQ revenue growth and flat operational metrics, underscoring high-risk development plays. Rallybio's merger includes CVRs tied to a July 8, 2025, Recursion Pharmaceuticals deal, introducing contingent value amid post-merger compliance hurdles like 12-month Form S-3 ineligibility. AmperCap's SPAC structure deposits proceeds into a trust for a 24-month business combination window, with $2.5M underwriting discounts and $4M working capital needs. Portfolio-level patterns show biotech M&A activity intersecting with SPAC launches, signaling potential thaw in risk-on IPO markets. Critical implications include merger catalyst timing for Rallybio and SPAC pricing appetite for AmperCap, with no insider activity or capital allocation trends reported across filings.
Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from March 16, 2026.
Investment Signals(12)
- Rallybio Corp↓(BULLISH)▲
Merger agreement dated March 1, 2026, advancing to S-4 filing just 16 days later, indicating accelerated execution
- Rallybio Corp↓(BULLISH)▲
CVRs contingent on July 8, 2025, Membership Interest Purchase Agreement with Recursion Pharmaceuticals, providing legacy asset upside
- Rallybio Corp↓(BULLISH)▲
Post-merger Super 8-K and Form S-8 eligibility after 60 days signal structured path to full SEC compliance
- AmperCap(BULLISH)▲
$125M IPO (upsized to $143.75M with over-allotment) at $10/unit reflects strong sponsor commitment for business combination
- AmperCap(BULLISH)▲
Incorporated December 5, 2025, with rapid S-1 filing (3+ months later) shows efficient ramp to market
- AmperCap(BULLISH)▲
Emerging Growth Company status reduces public reporting burdens vs standard IPOs, aiding deal focus
- Rallybio Corp↓(BULLISH)▲
Mixed sentiment driven by merger progress outweighing risks, materiality 9/10 vs AmperCap's neutral 10/10
- AmperCap(NEUTRAL)▲
No revenues since inception (0% YoY growth) but standard for SPACs, proceeds fully trusted for de-SPAC
- Rallybio Corp↓(NEUTRAL)▲
No period-over-period operational metrics due to development stage, but prior Recursion deal (July 2025) as baseline
- AmperCap(BULLISH)▲
24-month business combination window from IPO close provides extended runway vs typical 18-24 month peers
- Rallybio Corp↓(BULLISH)▲
Combined company formation enhances scale in biotech, relative to standalone pre-merger profile
- AmperCap(NEUTRAL)▲
Underwriting discounts at $2.5M (2% of base) align with sector norms, no excessive fees flagged
Risk Flags(10)
- Rallybio/CVR Risk↓[HIGH RISK]▼
CVRs may expire valueless if legacy assets not monetized per July 8, 2025, Recursion agreement
- Rallybio/Tax Uncertainty↓[HIGH RISK]▼
Potential adverse tax treatment on CVR payments, subordinating equityholder recoveries
- Rallybio/Compliance Burden↓[HIGH RISK]▼
12 full calendar months ineligible for Form S-3 post-closing, delaying shelf registrations
- Rallybio/Resale Restrictions↓[MEDIUM RISK]▼
Affiliates face resale limitations post-merger, impacting liquidity
- AmperCap/No Revenues[HIGH RISK]▼
Zero revenues since December 5, 2025, incorporation (flat QoY trend), highlighting speculative nature
- AmperCap/Investment Risk[HIGH RISK]▼
Explicit high-risk disclosure with no Rule 419 trust protections, redemption risks implied
- AmperCap/Costs[MEDIUM RISK]▼
$2.5M underwriting + $4M working capital/fees erode trust proceeds pre-de-SPAC
- Rallybio/Merger Execution↓[MEDIUM RISK]▼
Subsequent event merger (March 1, 2026) carries integration risks vs AmperCap's simpler SPAC structure
- AmperCap/24-Month Window[HIGH RISK]▼
Failure to complete business combination within 24 months from IPO triggers liquidation
- Rallybio/Sentiment↓[MEDIUM RISK]▼
Mixed outlook (9/10 materiality) due to subordination risks, underperforming AmperCap's neutral profile
Opportunities(10)
- Rallybio/Merger Closing↓(OPPORTUNITY)◆
Successful Candid merger unlocks combined entity value, monitor Super 8-K for timing
- Rallybio/CVR Milestone↓(OPPORTUNITY)◆
Monetization of Recursion-tied assets (July 2025 deal) could deliver outsized contingent payouts
- Rallybio/S-8 Path↓(OPPORTUNITY)◆
Form S-8 eligibility 60 days post-Super 8-K enables employee equity incentives, signaling growth
- AmperCap/SPAC IPO(OPPORTUNITY)◆
$125M raise (potential $143.75M) offers early access to de-SPAC alpha in thawing market
- AmperCap/EGC Benefits(OPPORTUNITY)◆
Reduced reporting vs non-EGCs allows agile pursuit of targets within 24 months
- AmperCap/Trust Yield(OPPORTUNITY)◆
IPO proceeds trusted at risk-free rates provide downside protection pre-business combination
- Rallybio/Biotech Consolidation↓(OPPORTUNITY)◆
S-4 reflects M&A momentum, relative undervaluation vs standalone IPO path
- AmperCap/Roadshow(OPPORTUNITY)◆
Recent S-1 filing positions for near-term pricing, gauge investor appetite vs 2025 SPAC slowdown
- Rallybio/Asset Flip↓(OPPORTUNITY)◆
Recursion Purchase Agreement success flips legacy holdings into cash, boosting pro forma balance sheet
- AmperCap/Over-Allotment(OPPORTUNITY)◆
15% upsizing potential signals scalable raise, outperforming smaller SPAC peers
Sector Themes(6)
- SPAC Renaissance◆
AmperCap's $125M S-1 (post-Dec 2025 inc.) indicates sponsor return after 2025 lull, with 24-month windows standard [IMPLICATION: Rising de-SPAC pipeline, monitor pricing for market sentiment]
- Biotech Merger Surge◆
Rallybio-Candid S-4 (Mar 2026) highlights consolidation via reverse mergers, mixed sentiment from CVRs [IMPLICATION: Alpha in deal breakups or CVR resolutions vs pure IPOs]
- Pre-Revenue Dominance◆
2/2 filings show 0% YoY revenue growth, flat metrics; neutral/mixed sentiments prevail [IMPLICATION: Risk-on shift favors spec plays, volatility from no ops history]
- Post-Deal Compliance Drag◆
Rallybio's 12-mo S-3 ineligibility + 60-day S-8 wait common in mergers vs SPACs [IMPLICATION: Delayed capital raises pressure balance sheets]
- Contingent Value Instruments◆
Rallybio CVRs tied to 2025 Recursion deal introduce binary outcomes across biotech [IMPLICATION: Hedge via shorts on failure scenarios]
- Cayman SPAC Prevalence◆
AmperCap exemplifies exempted company structure, $10/unit norm with EGC perks [IMPLICATION: Tax/structural edges drive outperformance in redemptions]
Watch List(8)
Track Super 8-K filing for exact closing date and pro forma details [Post-03-17-2026]
Monitor monetization of legacy assets under July 8, 2025, Recursion agreement [Ongoing to expiration]
12 full calendar months post-closing for shelf registration access [~2027]
60 days after Super 8-K for employee stock plans [~Q3 2026]
- AmperCap/IPO Pricing👁
Roadshow and unit pricing post-S-1 effectiveness [Imminent from 03-17-2026]
- AmperCap/Business Combination👁
24-month deadline from IPO close for target announcement [~March 2028]
- AmperCap/Over-Allotment👁
Exercise of 15% option for $18.75M additional proceeds [14 days post-IPO]
Restrictions lift timeline tied to merger close [Post-closing 2026]
Filing Analyses(2)
17-03-2026
Rallybio Corp filed an S-4 registration statement on March 17, 2026, related to a merger with Candid Therapeutics, forming a combined company with increased SEC compliance burdens post-closing, including a Super 8-K filing, 12-month ineligibility for Form S-3, and restrictions on resales for affiliates. Rallybio equityholders will receive CVRs contingent on monetizing legacy assets and cash proceeds from a July 8, 2025, Membership Interest Purchase Agreement with Recursion Pharmaceuticals, which may expire valueless if unsuccessful. The filing outlines risks such as tax uncertainty on CVRs and subordination of CVR payments.
- ·Merger agreement dated as a subsequent event on 2026-03-01.
- ·Membership Interest Purchase Agreement dated July 8, 2025.
- ·Combined company ineligible for Form S-3 for 12 full calendar months post-Closing; must wait 60 days post-Super 8-K for Form S-8.
- ·Combined company 'ineligible issuer' for three years post-Closing, restricting Form S-1 incorporation, free writing prospectuses, and WKSI status.
- ·Rule 144(i)(2) limits resale of restricted/control securities for one year after Form 10 filing.
17-03-2026
AmperCap Acquisition Company, a Cayman Islands blank check company incorporated on December 5, 2025, filed an S-1 registration statement for a $125M IPO (or $143.75M if over-allotment exercised) of units at $10.00 each, with proceeds primarily deposited into a trust account for a business combination within 24 months. The company has generated no revenues to date and highlights high investment risk with no Rule 419 protections. Underwriting discounts total $2.5M, with additional fees and working capital estimated at $4M.
- ·Incorporated December 5, 2025, as Cayman Islands exempted company.
- ·24-month completion window from IPO closing for business combination.
- ·Emerging growth company with reduced public reporting requirements.
- ·Units expected to list on NASDAQ as APMC and APMCW post-separate trading.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 2 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)